An Exploratory Study of Lurbinectedin With Radiotherapy in Locally-advanced SCLC After First-line Therapy

Inclusion Criteria

• •Has fully understood this study, voluntarily signed a written informed consent form, and is able to comply with the requirements and restrictions listed in the informed consent form;
• •Age ≥ 18 years, Male/female participants;
• •Has an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 2;
• •With pathologically confirmed diagnosis of Limited Stage SCLC(LS-SCLC),with local progression (mainly thoracic progression) after first-line chemotherapy with or without immunotherapy, but without distant metastasis; (Currently immunotherapy + chemotherapy is not the standard treatment for LS-SCLC);
• •Has sufficient bone marrow, liver, kidney, and metabolic function, i.e., the functional levels of organs meet the following requirements:
• •Platelets (PLT) ≥ 100×10\^9/L;
• •Hemoglobin (Hb) ≥ 90 g/L;
• •Absolute neutrophil (ANC) ≥ 2.0×10\^9/L;
• •Regardless of whether liver metastasis is present, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3.0× upper limit of normal (ULN);
• •Alkaline phosphatase (ALP) ≤ 5×ULN;
• •Total bilirubin (TBIL) ≤ 1.5×ULN, and direct bilirubin ≤ 1.0×ULN;
• •Serum creatinine ≤ 1.5×ULN or creatinine clearance rate ≥ 30 mL/min (calculated using the Cockcroft-Gault formula);
• •Creatine phosphokinase (CPK) ≤ 2.5×ULN;
• •Albumin ≥ 3.0 g/dL.
• •A female of childbearing potential (FCBP) must have a negative serum pregnancy test prior to study entry. Woman of childbearing potential (WOCBP) must use adequate contraception during the test drug treatment period and for 6 months after the final dose. Male patients (with partners of WOCBP) must use adequate contraception for the duration of study participation, and 4 months after completion of administration.